Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Cash from Investing Activities: 2016-2024

Historic Cash from Investing Activities for Dianthus Therapeutics (DNTH) over the last 9 years, with Dec 2024 value amounting to -$286.8 million.

  • Dianthus Therapeutics' Cash from Investing Activities rose 22.40% to -$201.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$183.1 million, marking a year-over-year increase of 32.65%. This contributed to the annual value of -$286.8 million for FY2024, which is 1516.15% down from last year.
  • Per Dianthus Therapeutics' latest filing, its Cash from Investing Activities stood at -$286.8 million for FY2024, which was down 1,516.15% from $20.3 million recorded in FY2023.
  • Over the past 5 years, Dianthus Therapeutics' Cash from Investing Activities peaked at $43.4 million during FY2021, and registered a low of -$286.8 million during FY2024.
  • Moreover, its 3-year median value for Cash from Investing Activities was -$59.8 million (2022), whereas its average is -$108.8 million.
  • Per our database at Business Quant, Dianthus Therapeutics' Cash from Investing Activities surged by 508.35% in 2021 and then crashed by 1,516.15% in 2024.
  • Over the past 5 years, Dianthus Therapeutics' Cash from Investing Activities (Yearly) stood at -$10.6 million in 2020, then surged by 508.35% to $43.4 million in 2021, then plummeted by 237.74% to -$59.8 million in 2022, then soared by 133.86% to $20.3 million in 2023, then plummeted by 1,516.15% to -$286.8 million in 2024.